Up­dat­ed: 2sev­en­ty lays off 40% of staff, prunes CAR-T pipeline as Nick Leschly steps down as CEO

With an ear­ly-stage CAR-T un­der clin­i­cal hold, 2sev­en­ty bio is slash­ing its head­count by 40% and cap­ping spend­ing on some pipeline pro­grams to fo­cus on grow­ing its ap­proved BC­MA ther­a­py.

2sev­en­ty is elim­i­nat­ing 176 roles as part of the lay­offs. Nick Leschly — who’s led the com­pa­ny for near­ly 14 years, since be­fore its spin­out from blue­bird bio — is al­so plan­ning to step down as CEO, with plans to be­come chair­man once the board finds his suc­ces­sor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER